Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.

The structure-based design, chemical synthesis, and biological evaluation of various 2-pyridone-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of a peptidomimetic binding determinant and a Michael acceptor moiety, which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. The 2-pyridone-containing inhibitors typically display improved 3CP inhibition properties relative to related peptide-derived molecules along with more favorable antiviral properties. The cocrystal structure of one pyridone-derived 3CP inhibitor complexed with HRV-2 3CP is also described along with certain ab initio conformation analyses. Optimization of the 2-pyridone-containing compounds is shown to provide several highly active 3CP inhibitors (k(obs)/[I] > 500,00 M(-1) s(-1)) that function as potent antirhinoviral agents (EC(50) = <0.05 microM) against multiple virus serotypes in cell culture. One 2-pyridone-containing 3CP inhibitor is shown to be bioavailable in the dog after oral dosing (F = 48%).

[1]  R. Conradi,et al.  The Influence of Peptide Structure on Transport Across Caco-2 Cells. II. Peptide Bond Modification Which Results in Improved Permeability , 1992, Pharmaceutical Research.

[2]  R. Conradi,et al.  The Influence of Peptide Structure on Transport Across Caco-2 Cells , 1991, Pharmaceutical Research.

[3]  J. Tao,et al.  An efficient synthesis of a key intermediate for the preparation of the rhinovirus protease inhibitor AG7088 via asymmetric dianionic cyanomethylation of N-Boc-l-(+)-glutamic acid dimethyl ester , 2001 .

[4]  P. Dragovich.  Recent advances in the development of human rhinovirus 3C protease inhibitors , 2001 .

[5]  V. Racaniello.  Picornaviridae : the viruses and their replication , 2001 .

[6]  F. Hayden,et al.  In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. , 2000, Antiviral research.

[7]  H. Rotbart.  Antiviral Therapy for Enteroviruses and Rhinoviruses , 2000, Antiviral chemistry & chemotherapy.

[8]  M. James,et al.  Proteolytic Enzymes of the Viruses of the Family Picornaviridae , 1999, Proteases of Infectious Agents.

[9]  D. Matthews,et al.  In Vitro Antiviral Activity of AG7088, a Potent Inhibitor of Human Rhinovirus 3C Protease , 1999, Antimicrobial Agents and Chemotherapy.

[10]  D. Matthews,et al.  Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Matthews,et al.  Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids. , 1999, Bioorganic & medicinal chemistry letters.

[12]  C. Hamdouchi,et al.  Short synthesis and anti-rhinoviral activity of imidazo[1,2-a]pyridines: the effect of acyl groups at 3-position. , 1999, Bioorganic & medicinal chemistry letters.

[13]  P. Dragovich,et al.  Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides. , 1999, Bioorganic & medicinal chemistry.

[14]  D. Matthews,et al.  Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. , 1999, Journal of medicinal chemistry.

[15]  D. Matthews,et al.  Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. , 1999, Journal of medicinal chemistry.

[16]  S. L. Gwaltney,et al.  Vinyl Sulfonate Esters and Vinyl Sulfonamides: Potent, Irreversible Inhibitors of Cysteine Proteases. , 1999 .

[17]  Rogers Jm,et al.  Pleconaril. A broad spectrum antipicornaviral agent. , 1999 .

[18]  Paul R. Caron,et al.  Chapter 29. Structure-Based Drug Design , 1999 .

[19]  M. Mckinlay,et al.  Pleconaril. A broad spectrum antipicornaviral agent. , 1999, Advances in experimental medicine and biology.

[20]  Q. Wang,et al.  Protease inhibitors as potential antiviral agents for the treatment of picornaviral infections. , 1999, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[21]  Q. Wang,et al.  Human rhinovirus 3C protease inhibitors: recent developments , 1998 .

[22]  S. Venkatraman,et al.  Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication. , 1998, Journal of medicinal chemistry.

[23]  D. Matthews,et al.  Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. , 1998, Journal of medicinal chemistry.

[24]  D. Matthews,et al.  Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements. , 1998, Journal of medicinal chemistry.

[25]  D. Matthews,et al.  Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. , 1998, Journal of medicinal chemistry.

[26]  J. Vacca,et al.  L‐373,890, an Achiral, Noncovalent, Subnanomolar Thrombin Inhibitor. , 1997 .

[27]  R. Nutt,et al.  Design and Synthesis of a Novel Class of Thrombin Inhibitors Incorporating Heterocyclic Dipeptide Surrogates. , 1997 .

[28]  M. Szelke,et al.  Pyridone‐Based Peptidomimetic Inhibitors of Interleukin‐1β‐ converting Enzyme (ICE). , 1997 .

[29]  G. Bemis,et al.  Structure-based design of non-peptidic pyridone aldehydes as inhibitors of interleukin-1β converting enzyme , 1997 .

[30]  R. Babine,et al.  MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN , 1997 .

[31]  R. Nutt,et al.  Design and synthesis of a novel class of thrombin inhibitors incorporating heterocyclic dipeptide surrogates , 1997 .

[32]  Mary E. McGrath,et al.  Crystal structure of human cathepsin K complexed with a potent inhibitor , 1997, Nature Structural Biology.

[33]  E. Arnold,et al.  Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14. , 1996, Journal of molecular biology.

[34]  J. Palmer,et al.  Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. , 1996, The Biochemical journal.

[35]  W. Guida,et al.  The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.

[36]  Alan R. Katritzky,et al.  Comprehensive Heterocyclic Chemistry IV , 1996 .

[37]  G. Cahiez,et al.  Enantioselective preparation of a-acyloxy ketones from a-hydroxy and a-amino acids , 1995 .

[38]  J. Palmer,et al.  Vinyl sulfones as mechanism-based cysteine protease inhibitors. , 1995, Journal of medicinal chemistry.

[39]  T. J. Nitz,et al.  Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. , 1995, Journal of medicinal chemistry.

[40]  Luis Carrasco.  Picornavirus inhibitors , 1994, Pharmacology & Therapeutics.

[41]  P. Warner,et al.  Non-peptidic inhibitors of human leukocyte elastase. 1. The design and synthesis of pyridone-containing inhibitors. , 1994, Journal of medicinal chemistry.

[42]  C L Verlinde,et al.  Structure-based drug design: progress, results and challenges. , 1994, Structure.

[43]  D. Matthews,et al.  Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein , 1994, Cell.

[44]  Marc Allaire,et al.  Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases , 1994, Nature.

[45]  J J Baldwin,et al.  Application of the three-dimensional structures of protein target molecules in structure-based drug design. , 1994, Journal of medicinal chemistry.

[46]  R. Hanzlik,et al.  Structure-activity relationships for inhibition of papain by peptide Michael acceptors. , 1992, Journal of medicinal chemistry.

[47]  K. Andries,et al.  In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity , 1992, Antimicrobial Agents and Chemotherapy.

[48]  M. Rossmann,et al.  Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. , 1992, Annual review of microbiology.

[49]  B. Rosenwirth,et al.  Biologically active protease 3C of human rhinovirus 1A is expressed from a cloned cDNA segment in Escherichia coli. , 1991, Virology.

[50]  D. Dess,et al.  A useful 12-I-5 triacetoxyperiodinane (the Dess-Martin periodinane) for the selective oxidation of primary or secondary alcohols and a variety of related 12-I-5 species , 1991 .

[51]  V. Garsky,et al.  Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro. , 1990, The Journal of biological chemistry.

[52]  V. Garsky,et al.  Cleavage of small peptides in vitro by human rhinovirus 14 3C protease expressed in Escherichia coli , 1989, Journal of virology.

[53]  B. Dunn,et al.  Hydrolysis of a series of synthetic peptide substrates by the human rhinovirus 14 3C proteinase, cloned and expressed in Escherichia coli. , 1989, The Journal of general virology.

[54]  K. Okuma,et al.  Reactions of Wittig reagents with episulfides or elemental sulfur. , 1988 .

[55]  R. Fletterick,et al.  Viral cysteine proteases are homologous to the trypsin-like family of serine proteases: structural and functional implications. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[56]  S. Takechi,et al.  A new amidoalkynylation using alkynylzinc reagent , 1988 .

[57]  E. Wimmer,et al.  Viral proteinases. , 1988, Annual review of biochemistry.

[58]  P. Minor,et al.  The nucleotide sequence of human rhinovirus 1B: molecular relationships within the rhinovirus genus. , 1988, The Journal of general virology.

[59]  W. S. Jordan,et al.  A collaborative report: rhinoviruses--extension of the numbering system from 89 to 100. , 1987, Virology.

[60]  W. Sommergruber,et al.  Evolutionary relationships within the human rhinovirus genus: comparison of serotypes 89, 2, and 14. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[61]  B. Rosenwirth,et al.  Molecular cloning and sequence determination of the genomic regions encoding protease and genome-linked protein of three picornaviruses , 1986, Journal of virology.

[62]  V. Blinov,et al.  Poliovirus‐encoded proteinase 3C: a possible evolutionary link between cellular serine and cysteine proteinase families , 1986, FEBS letters.

[63]  F. Fraundorfer,et al.  Human rhinovirus 2: complete nucleotide sequence and proteolytic processing signals in the capsid protein region. , 1985, Nucleic acids research.

[64]  L. Overman,et al.  A convenient synthesis of 4-unsubstituted .beta.-lactams , 1985 .

[65]  S. Mizutani,et al.  Molecular cloning and complete sequence determination of RNA genome of human rhinovirus type 14. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[66]  L. Overman,et al.  A CONVENIENT SYNTHESIS OF 4-UNSUBSTITUTED β-LACTAMS , 1985 .

[67]  D. Tyrrell,et al.  Rhinovirus colds. , 1985, British medical bulletin.

[68]  K. Albizati,et al.  Synthesis and nucleophilic substitutions of 3-alkyl-5-chloroisoxazoles , 1985 .

[69]  R. Mountford,et al.  The complete nucleotide sequence of a common cold virus: human rhinovlrus 14 , 1984 .

[70]  R. Hanzlik,et al.  Vinylogous amino acid esters: a new class of inactivators for thiol proteases. , 1984, Journal of medicinal chemistry.

[71]  R. Mountford,et al.  The complete nucleotide sequence of a common cold virus: human rhinovirus 14. , 1984, Nucleic acids research.

[72]  Edwin H. Lennette,et al.  Rhinoviruses , 1968 .

[73]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[74]  T. Heikkinen,et al.  The common cold , 2003, The Lancet.